Comparative incidence and health care costs of medically attended adverse effects among U.S. medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy

Value in Health

Volumn 16, Issue 2, 2013, Pages 418-425

  Johnston, Stephen S ^a   Juday, Timothy ^b   Esker, Stephen ^b   Espindle, Derek ^a   Chu, Bong Chul ^a   Hebden, Tony ^b   Uy, Jonathan ^b  

^a IBM WATSON HEALTH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

adverse effects; antiretroviral therapy; atazanavir; darunavir; health care costs; Medicaid

Indexed keywords

ABACAVIR; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ATAZANAVIR; BIGUANIDE DERIVATIVE; CALAMINE; DARUNAVIR; DIDANOSINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMTRICITABINE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAMIVUDINE; MEGLITINIDE; NICOTINIC ACID; RESIN; STAVUDINE; SULFONYLUREA; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ADVERSE DRUG REACTION; ANTIVIRAL THERAPY; ARTICLE; BILLING AND CLAIMS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG COST; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INCIDENCE; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MEDICAID; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84875417244     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.10.021     Document Type: Article

References (24)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. 1-239. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed April 1, 2012].
2. A. d'Arminio Monforte, A.C. Lepri, and G. Rezza Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients AIDS 14 2000 499 507
3. M.P. Dube, J.H. Stein, and J.A. Aberg Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clin Infect Dis 37 2003 613 627
4. J.H. Stein, Y. Wu, and H. Kawabata Iloeje Uh. Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors Am J Cardiol 92 2003 270 274
5. R. Kantor, R.W. Shafer, and S. Follansbee Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy AIDS 18 2004 1503 1511
6. S. Napravnik, D. Edwards, and P. Stewart HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia J Acquir Immune Defic Syndr 40 2005 34 40
7. M.A. Thompson, J.A. Aberg, and P. Cahn Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 2010 321 333
8. C. Hicks, J. Currier, and P. Sax Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications AIDS Patient Care STDS 17 2003 221 233
9. D. González de Requena, F. Blanco, and T. Garcia-Benayas Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir AIDS Patient Care STDS 17 2003 443 445
10. K.M. Korenblat, and P.D. Berk Hyperbilirubinemia in the setting of antiviral therapy Clin Gastroenterol Hepatol 3 2005 303 310
11. AIDS Clinical Trials Group. Comparative study of three NNRTI-sparing HAART regimens. 2000 Available from: http://clinicaltrials.gov/ct2/show/ NCT00811954?term=ACTG+5257&rank=3 NLM Identifier:NCT00811954. [Accessed April 13, 2012].
12. S.A. Bozzette, S.H. Berry, and N. Duan The care of HIV-infected adults in the United States N Engl J Med 339 1998 1897 1904
13. J.A. Fleishman, K.A. Gebo, and E.D. Reilly Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002 Med Care 43 9, Suppl. 2005 III40 III52
14. C. Torti, G. Lapadula, and A. Antinori Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts Infection 37 2009 244 249
15. M. Segarra-Newnham Hyperlipidemia in HIV-positive patients receiving antiretrovirals Ann Pharmacother 36 2002 592 595
16. Consumer price index detailed report tables annual average 2010. Available from: http://www.bls.gov/cpi/cpid10av.pdf. [Accessed March 1, 2011].
17. R.B. D'Agostino Jr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
18. W.H. Rogers Regression standard errors in clustered samples Stata Technic Bull 13 1993 19 23
19. A. Hill, and A. Balkin Risk factors for gastrointestinal adverse events in HIV treated and untreated patients AIDS Rev 11 2009 30 38
20. J.A. Aberg, P. Tebas, and E.T. Overton Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks AIDS Res Hum Retroviruses 28 2012 1184 1195
21. Carr A, Amin J. Reasons for treatment success with initial ART: an analysis of 2,635 participants in 64 randomized, controlled trials and 14 prospective cohorts. Presented at: 15th Conference on Retrovirus and Opportunistic Infections (CROI); February 3-6, 2008; Boston, MA. Abstract 782.
22. A.M. Mills, M. Nelson, and D. Jayaweera Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive HIV-1-infected patients: 96-week analysis. AIDS 23 2009 1679 1688
23. B. Clotet, N. Bellos, and J.M. Molina Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178
24. Reyataz [package insert] 2012 Bristol-Myers Squibb NJ